On May 19, 2022 Mevion Medical Systems reported that it has been selected to install a MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS) in a comprehensive hospital in Southern China (Press release, Mevion Medical Systems, MAY 19, 2022, View Source [SID1234614875]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Proton therapy is a superior form of radiation therapy that can reduce the amount of unnecessary radiation exposure to surrounding healthy tissue and sensitive organs at risk. HYPERSCAN PBS improves on these benefits by using Mevion’s unique Adaptive Aperture pMLC to enable faster and sharper delivery of therapeutic radiation to tumors while sparing healthy tissue.

The MEVION S250i Proton Therapy System’s leading-edge clinical capabilities, combined with its compact, affordable design, and industry-leading ramp-up time, have changed the landscape of proton therapy. Mevion received US FDA 510(k) clearance for the system in 2017 and is actively seeking regulatory approval from the National Medical Products Administration (NMPA) in China.

"We are proud to be selected to equip a new proton center in Southern China," said Tina Yu, Ph.D., CEO and President of Mevion Medical Systems. "It confirms Mevion’s leading position as a trusted compact proton therapy provider and marks another milestone of our growth in China."

According to Global Cancer Observatory, there were over 4.5 million cancer cases in China in 2020. However, only 3 proton centers are currently in clinical operation in Mainland China, leaving a substantial number of patients without access to this advanced cancer-fighting technology. As the innovator of the single-room system, Mevion’s approach allows for an expedited project timeline, efficient center operation, and financial success, all of which will benefit the underserved China market.

On May 19, 2022 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, reported that John Butler, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference, which will take place as a hybrid event May 23–26, 2022 (Press release, Akebia, MAY 19, 2022, View Source/news-releases/news-release-details/akebia-therapeutics-present-hc-wainwright-global-investment" target="_blank" title="View Source/news-releases/news-release-details/akebia-therapeutics-present-hc-wainwright-global-investment" rel="nofollow">View Source [SID1234614874]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An audio replay of the fireside chat will be available through the Investors section of Akebia’s website at View Source starting on May 24th and for approximately 90 days following the conference.

On May 19, 2022 Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, reported that James Oliviero, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference, on Wednesday, May 25, 2022, at 3:00 p.m. ET (Press release, Checkpoint Therapeutics, MAY 19, 2022, View Source [SID1234614873]). Checkpoint management will also participate in one-on-one meetings during the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Investor Relations Calendar page under News & Events, located within the Investors section of Checkpoint’s website, View Source, for approximately 30 days following the meeting.

On May 19, 2022 Vyant Bio, Inc. ("Vyant Bio" or "Company") (Nasdaq: VYNT), is an innovative biotechnology company reported that reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders (Press release, Vyant Bio, MAY 19, 2022, View Source [SID1234614872]). The Company’s central nervous system ("CNS") drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it will be participating in the H.C. Wainwright Global Investment Hybrid Conference. The event is being held from May 23-26, 2022. Registered attendees can access the recorded presentation on-demand (24×7) for the duration of the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the presentation, Vyant Bio’s Chief Executive Officer, Jay Roberts will be discussing key milestones and achievements on the scientific, business, and strategic fronts. The presentation slides will also be available in the Investors’ section of the Vyant Bio website.

If you are an institutional investor and would like to participate in this event, please click on the following link (View Source) to register for the H.C. Wainwright Global Investment Hybrid Conference. Once your registration is confirmed, you will be prompted to log into the conference website and will be able to request a one-on-one meeting with the Company.

Vyant Bio will also be available for virtual outside 1:1 meetings after the H.C. Wainwright Global Investment Hybrid Conference. Please contact Jennifer K. Zimmons, PhD at [email protected] or +1 917.214.3514 for scheduling.

On May 19, 2022 AIM ImmunoTech Inc. (NYSE: American AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, reported that Thomas K. Equels, M.S. J.D., Chief Executive Officer of AIM, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually (Press release, AIM ImmunoTech, MAY 19, 2022, https://aimimmuno.com/press-release/aim-immunotech-to-present-at-the-h-c-wainwright-global-investment-conference/ [SID1234614871]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.

A video webcast of the presentation will be accessible for viewing on-demand beginning on Tuesday, May 24, 2022, at 7:00 AM ET for those registered for the event and will be available on the Events page in the Investor Relations section of the Company’s website (aimimmuno.com). The webcast replay will be archived for 90 days following the event.